On 17 August 2013, orphan designation (EU/3/13/1154) was granted by the European Commission to Diamond BioPharm Limited, United Kingdom, for fosbretabulin tromethamine for the treatment of ovarian cancer.
- What is ovarian cancer?
Ovarian cancer is cancer of the ovaries, the two organs in the female reproductive system that produce eggs. Most ovarian cancers occur in women over the age of 50 years. Due to the absence of symptoms in the early stages of the disease, the majority of patients are diagnosed when the cancer has spread to other parts of the body.
Ovarian cancer is a life-threatening disease that is associated with poor long-term survival.
- What is the estimated number of patients affected by the condition?
At the time of designation, ovarian cancer affected approximately 2 in 10,000 people in the European Union (EU). This was equivalent to a total of around 102,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. This represents a population of 509,000,000 (Eurostat 2013).
- What treatments are available?
At the time of designation, several medicines were authorised in the EU for the treatment of ovarian cancer. The choice of treatment depended mainly on how advanced the disease was. Treatments included surgery and chemotherapy (medicines to treat cancer).
The sponsor has provided sufficient information to show that fosbretabulin tromethamine might be of significant benefit for patients with ovarian cancer because studies suggest it might improve the treatment of ovarian cancers resistant to platinum treatments, when used in combination with the chemotherapy medicines carboplatin and paclitaxel. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
- How is this medicine expected to work?
Fosbretabulin tromethamine is a medicine that targets the cells of blood vessels supplying the tumour, disrupting small structures called microtubules within the cells which allow these cells to divide. By targeting these blood vessels, it is expected to cause the death of tumour cells by cutting off their blood supply, and thereby slow down the progression of the disease.
Fosbretabulin tromethamine is expected to be given in combination with other medicines (carboplatin and paclitaxel) that damage the cancer cells in different ways.
- What is the stage of development of this medicine?
The effects of fosbretabulin tromethamine have been evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials with fosbretabulin tromethamine in patients with ovarian cancer were ongoing.
At the time of submission, fosbretabulin tromethamine was not authorised anywhere in the EU for ovarian cancer. Orphan designation had been granted in the United States for the condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 13 June 2013 recommending the granting of this designation.
- Opinions on orphan medicinal product designations are based on the following three criteria:
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
|Name||Language||First published||Last updated|
|EU/3/13/1154: Public summary of opinion on orphan designation: Fosbretabulin tromethamine for the treatment of ovarian cancer||(English only)||21/08/2013|
|Active substance||Fosbretabulin tromethamine|
|Disease/condition||Treatment of ovarian cancer|
|Date of decision||17/07/2013|
|Orphan decision number||EU/3/13/1154|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor’s contact details
Diamond BioPharm Limited
No 4 East Wing, Gemini House
Tel. +44 (0)1279 441 616
Fax +44 (0)1279 418 964
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.